Replimune Group (REPL) to Resubmit Biologics License Application for RP1 to FDA

Replimune Group, Inc. announced its intention to resubmit its Biologics License Application (BLA) for RP1 (vusolimogene oderparepvec) in combination with nivolumab for the treatment of advanced melanoma. This decision follows collaborative communications with the U.S. Food and Drug Administration. The resubmission represents a key regulatory step for the biotechnology company and its potential melanoma treatment.